Version May 2024
Skeletal imaging: IV: 8 to 12 mCi (300 to 450 MBq).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Skeletal imaging: IV: Weight-based doses (0.06 mCi/kg [2.1 MBq/kg]) ranging from 0.5 to 4 mCi (19 to 148 MBq) were reported in clinical experience.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
No adverse events have been reported at this time.
There are no contraindications listed in the manufacturer’s labeling.
Disease-related concerns:
• Cancer: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.
Special populations:
• Pediatric: May localize in areas of bone turnover, including developing long bones. Children are more sensitive to radiation; therefore, the lowest radiation-absorbed dose should be utilized to minimize risk to the patient and provide quality imaging (Gelfand, 2011).
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel (eg, wear waterproof gloves and use effective shielding). Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Absorbed radiation: Bone, bone marrow, and urinary bladder are target organs for high absorbed radiation doses. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.
• Appropriate use: Imaging: Patients should void immediately before imaging the radioactivity in the lumbar spine or bony pelvis.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Generic: 10-200 mCi/mL (30 mL)
Yes
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Osteovision: 300 mCi/mL (10 mL, 30 mL)
Generic: 10-200 MCI/ML (30 mL)
IV: For IV administration. PET scan should begin 1 to 2 hours after administration. Wear waterproof gloves and use protective shielding when handling and administering sodium fluoride F18. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours. See manufacturer's prescribing information for complete administration procedure.
Radiopharmaceutical; use appropriate precautions for handling and disposal.
IV: For IV administration. See manufacturer's labeling for complete administration procedure. Wear waterproof gloves and use protective shielding when handling and administering sodium fluoride F18. PET scan should begin 1 to 2 hours after administration. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.
Radiopharmaceutical; use appropriate precautions for handling and disposal.
Skeletal imaging: Imaging agent used in conjunction with positron emission tomography (PET) for imaging of bone to define areas of altered osteogenic activity
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted. All radiopharmaceuticals have the potential to cause fetal harm.
Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended. The manufacturer recommends interrupting breast-feeding for ≥24 hours to minimize radioactivity exposure and risk to the infant.
To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.
Fluoride F18 ion accumulates in the skeleton with increased deposition in the vertebrae and pelvis to define areas of abnormal osteogenic activity.
Distribution: Blood, bone; only ~10% of dose remains in blood 1 hour after administration
Half-life elimination: Biexponential: First phase: 0.4 hours; Second phase: 2.6 hours
Excretion: Urine (≥20% within the first 2 hours after administration)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
